162 related articles for article (PubMed ID: 32950263)
21. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
22. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
[TBL] [Abstract][Full Text] [Related]
23. Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
Schirosi L; Strippoli S; Gaudio F; Graziano G; Popescu O; Guida M; Simone G; Mangia A
BMC Cancer; 2016 Nov; 16(1):905. PubMed ID: 27863476
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains.
Idikio HA
Int J Clin Exp Pathol; 2009 Nov; 3(2):169-76. PubMed ID: 20126585
[TBL] [Abstract][Full Text] [Related]
25. Application of in situ hybridization probes for MLH-1 and MSH-2 in tissue microarrays of paraffin-embedded malignant melanomas: correlation with immunohistochemistry and tumor stage.
Korabiowska M; Cordon-Cardo C; Jaenckel F; Stachura J; Fischer G; Brinck U
Hum Pathol; 2004 Dec; 35(12):1543-8. PubMed ID: 15619215
[TBL] [Abstract][Full Text] [Related]
26. Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Schmidt H; Steiniche T
Diagn Pathol; 2016 Apr; 11():35. PubMed ID: 27062658
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.
Sunshine JC; Nguyen PL; Kaunitz GJ; Cottrell TR; Berry S; Esandrio J; Xu H; Ogurtsova A; Bleich KB; Cornish TC; Lipson EJ; Anders RA; Taube JM
Clin Cancer Res; 2017 Aug; 23(16):4938-4944. PubMed ID: 28428193
[No Abstract] [Full Text] [Related]
28. Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma.
Phillips T; Millett MM; Zhang X; Jansson M; Cleveland R; Simmons P; Cherryholmes G; Carnahan J; William J; Spaulding B; Satnick IR; Inzunza HD; Taylor C; Cogswell J; Novotny J; Oroudjev E; Winther H
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):6-12. PubMed ID: 29189265
[TBL] [Abstract][Full Text] [Related]
29. [Immunohistochemistry using clone VE1 is an economic, specific and sensitive method for detecting the presence of BRAFV600E mutations in melanoma].
Etienne M; Oca F; Prunier-Mirebeau D; Croué A; Martin L
Ann Dermatol Venereol; 2018 Mar; 145(3):159-165. PubMed ID: 29221650
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
Schmoeckel E; Hofmann S; Fromberger D; Rottmann M; Luthardt B; Burges A; Jeschke U; Kirchner T; Lax SF; Mayr D
Virchows Arch; 2019 May; 474(5):599-608. PubMed ID: 30734108
[TBL] [Abstract][Full Text] [Related]
31. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
[TBL] [Abstract][Full Text] [Related]
32. Rapid frozen section immunostaining of melanocytes by microphthalmia-associated transcription factor.
Glass LF; Raziano RM; Clark GS; Higgins HW; Ladd S; Lien MH; Chen R; Cherpelis BS
Am J Dermatopathol; 2010 Jun; 32(4):319-25. PubMed ID: 20514666
[TBL] [Abstract][Full Text] [Related]
33. A Diagnostic Algorithm Combining Immunohistochemistry and Molecular Cytogenetics to Diagnose Challenging Melanocytic Tumors.
Redon S; Guibourg B; Talagas M; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2018; 26(10):714-720. PubMed ID: 28362709
[TBL] [Abstract][Full Text] [Related]
34. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
Tetzlaff MT; Pattanaprichakul P; Wargo J; Fox PS; Patel KP; Estrella JS; Broaddus RR; Williams MD; Davies MA; Routbort MJ; Lazar AJ; Woodman SE; Hwu WJ; Gershenwald JE; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2015 Aug; 46(8):1101-10. PubMed ID: 26058727
[TBL] [Abstract][Full Text] [Related]
35. Correlation of Immunocytochemistry of BRCA1-associated Protein-1 (BAP1) With Other Prognostic Markers in Uveal Melanoma.
Glasgow BJ; McCannel TA
Am J Ophthalmol; 2018 May; 189():122-126. PubMed ID: 29530782
[TBL] [Abstract][Full Text] [Related]
36. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F
J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic utility of epithelial and melanocitic markers with double sequential immunohistochemical staining in differentiating melanoma in situ from invasive melanoma.
Parra-Medina R; Morales SD
Ann Diagn Pathol; 2017 Feb; 26():70-74. PubMed ID: 27594302
[TBL] [Abstract][Full Text] [Related]
38. Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications.
Doghri R; Houcine Y; Boujelbène N; Driss M; Charfi L; Abbes I; Mrad K; Sellami R
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):678-682. PubMed ID: 31567138
[TBL] [Abstract][Full Text] [Related]
39. Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E Mutation.
Leblond AL; Rechsteiner M; Jones A; Brajkovic S; Dupouy D; Soltermann A
Am J Clin Pathol; 2019 Jun; 152(1):59-73. PubMed ID: 31065676
[TBL] [Abstract][Full Text] [Related]
40. Detection of DNA Mismatch Repair Protein Abnormalities in Sudanese Colorectal Cancer Patients Using Immunohistochemical Methods.
Zakout YM; Lanza G
J Gastrointest Cancer; 2019 Sep; 50(3):530-536. PubMed ID: 29850986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]